{"organizations": [], "uuid": "bb0582c50aeab1ea57830c64119fe197862e03e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-genentech-says-follow-up-phase-3-d/brief-genentech-says-follow-up-phase-3-data-showed-alecensa-reduced-risk-of-disease-progression-by-57-pct-idUSFWN1SN110", "country": "US", "domain_rank": 408, "title": "BRIEF-Genentech Says Follow-Up Phase 3 Data Showed Alecensa Reduced Risk Of Disease Progression By 57 Pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-05-17T05:16:00.000+03:00", "replies_count": 0, "uuid": "bb0582c50aeab1ea57830c64119fe197862e03e1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genentech-says-follow-up-phase-3-d/brief-genentech-says-follow-up-phase-3-data-showed-alecensa-reduced-risk-of-disease-progression-by-57-pct-idUSFWN1SN110", "ord_in_thread": 0, "title": "BRIEF-Genentech Says Follow-Up Phase 3 Data Showed Alecensa Reduced Risk Of Disease Progression By 57 Pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "genentech", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Genentech:\n* FOLLOW-UP PHASE III DATA SHOWED GENENTECHâ€™S ALECENSA HELPED PEOPLE WITH ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER LIVE A MEDIAN OF ALMOST THREE YEARS WITHOUT THEIR DISEASE WORSENING OR DEATH\n* GENENTECH - FOLLOW-UP PHASE III DATA SHOWED ALECENSA REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 57 PERCENT VERSUS CRIZOTINIB IN PEOPLE WITH ALK-POSITIVE METASTATIC NSCLC Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T05:16:00.000+03:00", "crawled": "2018-05-17T01:45:53.000+03:00", "highlightTitle": ""}